Social inequalities in lawsuits for drugs by Provin, Mércia Pandolfo et al.
*Correspondence: M. P. Provin. Faculdade de Farmácia, Universidade Federal 
de Goiás. Avenida Universitária, Campus I, Setor Universitário, 74605-220 - 
Goiânia-GO, Brasil. E-mail: merciap@gmail.com
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 49, n. 3, jul./sep., 2013
Social inequalities in lawsuits for drugs
Mércia Pandolfo Provin1,*, Silvana Nair Leite2, Rita Goreti Amaral3
1School of Pharmacy, Federal University of Goiás, Goiânia, GO, Brazil, 2Department of Pharmacy, Federal University of 
Santa Catarina, Florianopolis, SC, Brazil, 3School of Pharmacy, Federal University of Goiás, Goiânia, GO, Brazil 
The aim of this study was to characterize the lawsuits requesting drugs considering the economic profile 
of their petitioners. All lawsuits (1378) accepted against Goiânia, GO from 2003 to 2007 were analyzed. 
Petitioners’ demographic characteristics, reported diseases, requested drugs, origin of healthcare service, 
and lawsuit agent were described. Complainants’ addresses were georeferenced and distributed into  
4 regional groups classified in accordance with the population’s average income. Dwellers of wealthier 
regions filed court actions requesting drugs more frequently, with an average rate of 1.7 lawsuits/1000 
inhabitants versus 0.55/1000 in the poorer region. Lawsuit costs were 4-fold higher in wealthier regions 
compared with the poorest region. Chronic diseases were involved in most lawsuits, where acute and low 
complexity diseases predominated among complainants living in poorer regions. Thus, social differences 
were reflected in the granting of health rights.
Uniterms: Health rights. Drugs/access. Health inequalities. Health care.
Este estudo teve como objetivo caracterizar as ações judiciais que solicitaram medicamentos considerando 
o perfil econômico de seus impetrantes. Foram analisadas as ações judiciais deferidas contra Goiânia, 
GO, no período de 2003 a 2007, totalizando 1378. Descreveram-se as características demográficas dos 
impetrantes, as doenças relatadas, os medicamentos solicitados, a origem do serviço de assistência e o 
condutor da ação. Os endereços dos impetrantes foram geoprocessados e distribuídos em quatro grupos 
classificados de acordo com a renda média da população. Foi observado que os moradores de regiões 
ricas impetraram mais ações, 1,7 ações/1000 habitantes em comparação com 0,55/1000 na região mais 
pobre. Os custos das ações judiciais também foram maiores nessas regiões, sendo quatro vezes mais 
caros dos que as das regiões mais pobres. As doenças crônicas estavam presentes na maioria das ações; 
entre os impetrantes que moravam em regiões mais pobres, as doenças agudas e de menor complexidade 
tiveram mais destaque. Assim, as diferenças sociais são refletidas na concessão do direito à saúde.
Unitermos: Direito à saúde. Medicamentos/acesso público. Saúde/desigualdades de acesso.  Assistência 
a saúde.
INTRODUCTION
Access to health care services in Brazil is free, 
universal and grants full assistance to its users, include 
pharmaceutical. The Unified Health System (UHS 
or Sistema Único de Saúde - SUS in Portuguese) is 
organized into a hierarchical and regionalized network 
which provides assistance through its own health units 
or through affiliated private institutions (Brazil, 1988, 
1990).
However, in the last few years an increasing number 
of citizens have brought court actions to grant access to 
drugs prescribed for their treatments and this litigation 
has become a management and financial problem for the 
national and local health systems (Messeder, Osorio-de-
Castro, Luiza, 2005). This phenomenon has been coined 
health “judicialization”.
Some authors hold that lawsuits have become 
instruments of inequality in access and irrationality in use 
of public resources when they rule the provision of drugs 
which are not standard under the public health system or 
when they contravene SUS and Pharmaceutical Assistance 
regulations (Vieira, Zucchi, 2007; Silva, Terrazas, 2009). 
On the other hand, others recognize legitimacy in control 
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of public policy by the Judicial Powers in as far as this 
broadens the democratic debate to include the adoption 
of counter-majoritarian positions (Appio, 2007; Freire, 
2003). Positions in the conflicting literature reveal a lack 
of consensus on the issue.
Lawsuits requested a myriad of types of drugs, most 
of which were included in the official lists of drugs for 
public distribution, others presented standard therapeutic 
alternatives, while a small proportion represented 
assistance gaps or new technologies that have not yet been 
incorporated by the SUS (Messeder, Osorio-de-Castro, 
Luiza, 2005; Vieira, Zucchi, 2007; Pereira et al., 2003; 
Romero, 2008; Bonfim, 2008; Leite et al., 2009; Chieff, 
Barata, 2009; Borges, Ugá, 2010). Whether opposing the 
policies of public health or otherwise, the judicial demand 
for drugs may reflect the conditions of access to the health 
service by citizens.
The pattern of access to health services is strongly 
influenced by people’s social conditions and the 
availability of access to complementary private health 
(Travassos, Oliveira, Viacava, 2006; Silva et al.., 2000). 
Delay in provision of services, excess referral of patients 
to other services, shortage of doctors and deficiencies 
in the facilities are some aspects reported by users as 
shortcomings regarding the use of the public health system 
(Schwartz et al.., 2010).
Therefore, geographical and social differences are 
important as determinants of health and health services 
access. Analysis, for example, of the utilization rate of 
health services among different regions, cities and also 
on an intra-city basis, reveals the geographical dimension 
of the differences in local financing capability, individual 
access and the size and complexity of service networks 
available (Travassos, 1997).
In the case of drugs, access may be free and citizens 
have to join SUS and accept its whole set of technical-
organizational regulations, which include respecting its 
actions hierarchy, regionalization and standard procedures. 
Those citizens not accepting these conditions may opt for 
the supplementary private system, whose expenses are 
covered by the users through insurances or health plans. 
In these cases, the assistance offered is stipulated under 
the contractual terms and conditions. 
The judicial route, as previously discussed, has 
become a means of gaining access to drugs, but it is 
unclear whether litigation is an equalitarian solution or 
the extent to which social and geographical differences 
influence its characteristics.
Therefore, the objective of this study was to 
characterize the demand for drugs through the judicial 
route in regions with different incomes.
METHODOLOGY
A cross-sectional, descriptive study was carried 
out at the School of Pharmacy – Federal University of 
Goiás, previously approved by the Ethics Committee of 
the institution. The study involved the analysis of court 
actions demanding drugs that were accepted and granted 
at the city of Goiânia-GO-Brazil.
The study comprised all court actions demanding 
drugs brought against the city of Goiânia-GO that were 
accepted and received by the Unified Health System 
manager from January 2005 to December 2007.
Lawsuits which requested at least one drug and 
resulted in legal proceedings in the Municipal Nonessential 
Medication Pharmacy, the unit responsible for purchasing, 
storage and dispensing drugs, were included in the study. 
Lawsuits that did not request drugs or lacking full address 
for geoprocessing were excluded.
Data was collected using a standard form gathering 
information on subject of lawsuits, the petitioners and 
drugs involved, in addition to the health system that had 
made out the prescription. 
The variables of interest were: (a) court actions: 
number of lawsuits, year granted, agent guiding action, 
type of court action; (b) petitioner: petitioner number, 
basis and associated diseases reported, gender, age, place 
of residence, income; (c) origin of prescriptions; and (d) 
drugs: cost, availability of the pharmacological therapy 
and alternative therapeutics.
Due to the lack of information concerning the 
cost of each drug provided by the Municipal Health 
Secretariat/Goiânia, it was necessary to assign prices to 
them in accordance with the following strategy: for each 
pharmaceutical specialty requested, the reference drug 
was adopted according to definitions in Law No. 9787/99 
(Brazil, 1999), the value assigned to each provided item 
was drawn from the consumer price list consulted on the 
Brasíndice Pharmaceutical Guide, editions from 2003 to 
2007, considering a 17% taxation rate plus a 30% discount 
on the average profit of retail sales. Regarding drugs with 
floating price and/or imported, the prevailing market prices 
were used, and the deflation index applied for the period 
in question, to arrive at the hypothetical prices in the year 
of delivery.
Pharmacological therapy availability was analyzed 
by comparing the requested drugs against the Brazilian 
Common Denomination (BCD), and checking for 
their accessibility in the drugs lists of the Municipal 
List of Essential Drugs (LEM, Relação Municipal de 
Medicamentos Essenciais – REMUME in Portuguese) and 
the High Cost and Exceptional Circumstance Dispensing 
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Drugs Program, now called Specialized Component of 
Pharmaceutical Assistance (SCPA).
For analysis of the therapeutic alternative 
availability in the public health service, the requested 
drugs were compared with official lists that make the three 
components defined in the Pharmaceutical Assistance 
Policy: basic component, strategic component and 
exceptional dispensed drugs component. Those drugs not 
contained in any of the lists were included and classified 
based on the Anatomical Therapeutic Chemical (ATC) 
Classification System, proposed by the World Health 
Organization Collaborating Center (WHO) for drugs 
methodology, from Oslo, Norway and the International 
Working Group for Drug Statistics, located in Geneva, 
Switzerland, which defines the directives in applying this 
methodology (Word Health Organization, 2010). Drugs 
having a therapeutic alternative were considered those 
requested through court actions that belonged to the same 
therapeutic subgroup (3rd level in the ATC classification) 
as others present in the lists of the public health system.
In order to characterize the drugs demanded through 
the judicial route in different city regions and to determine 
the public coverage for pharmacological therapy, the 
court actions were processed and the related information 
present in the collection forms was consolidated using 
Microsoft Office Excel 2007. At this stage, 129 lawsuits 
were excluded for having incomplete data, giving a total 
of 1,249 lawsuits analyzed.
 Subsequently, the lawsuits from among 63 
Territorial Basic Units (TBU) of Goiânia were described 
and distributed by geoprocessing. These TPUs each 
correspond to a neighborhood or a set of neighborhoods, 
delimited by physical barriers, such as transport system, 
rivers and minor watercourses which split up parts of the 
urban space that have a significant level of homogeneity. 
The population data and the average income of the 
breadwinners (in Reais) of each TBU were gathered from 
the 2000 census data (Brasil, 2003). The average income 
was then converted into minimum wages at a reference 
amount of R$ 151.00 as defined in Law No. 9971 of 
05/18/2000.
After geoprocessing, the court actions were grouped 
in accordance with the estimated average income of the 
family breadwinner for the respective TBU, into four 
groups as follows:
·	 Region type I: set of court actions filed in regions 
where the average income is from 0 to 3 (included) 
minimum wages;
·	 Region type II: set of court actions filed regions whe-
re the average income is higher than 3 to 6 (included) 
minimum wages;
·	 Region type III: set of court actions filed in regions 
where the average income is higher than 6 to 9 (in-
cluded) minimum wages;
·	 Region type IV: set of court actions filed in regions 
where the average income is greater than 9 minimum 
wages.
The following sources were used: (a) for court action 
data, the suits filed at the Nonessential Drugs Pharmacy 
of the Municipal Health Secretariat; (b) for census data, 
the IBGE (Brasil, 2003); and (c) for drug costs, the 
Brasíndice Pharmaceutical Guide – 2005 to 2007, was 
employed.
The financial importance of each drug in the court 
action costs were analyzed for the two income extremes 
(Regions I and IV) using the Pareto Analysis, also known 
as the ABC curve, which allows them to be listed from 
most to least important, making it easier to visualize and 
identify those drugs which need most attention (Rosa, 
Gomes, 2001). The drugs were thus classified into three 
groups (A, B and C) according to their relative weight 
in the court action costs. After calculating the items’ 
relative costs, they were arranged in decreasing order. The 
groups A, B and C were then defined. Group A, of higher 
financial importance, corresponded to those drugs that, 
when added, represented 75% of costs. Drugs in group 
C, although corresponding to the largest proportion, only 
represented a low proportion of costs, at about 10%. Group 
B represented the intermediary cases between groups A 
and C. For the curve calculus, monetary values from 2007 
were used as a base.
After characterization and distribution of the 
demands for drugs though lawsuits in different regions 
of the city (TBUs), these were categorized into four 
groups according to the population’s median income and 
examined to determine whether the lawsuit characteristics 
varied according to income.
Analyzed variables were then compared for the 
income groups. It should be noted that for these analyses 
the sample units corresponded to the TBUs, i.e., when 
there is, for example, an average, this number represents 
the average of all TBUs that met the characteristics of the 
group. The Kruskal-Wallis test was applied since the data 
did not generally follow a normal distribution.
The following definition was used to identify the 
groups: 0-3 MW, monthly income of 0 to 3 minimum 
wages; 3-6 MW, average income of 3 to 6 minimum 
wages; 6-9 MW, average income of 6 to 9 minimum 
wages; and Over 9 MW, income higher than 9 minimum 
wages.
A level of significance of 0.05 was adopted for the 
tests.
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RESULTS
The survey carried out at the Non-Essential 
Pharmacy of Goiânia found 1,344 petitioning citizens who 
filed a total of 1,378 lawsuits demanding different drugs 
from January 2003 to December 2007.
The number of lawsuits filed per year rose from 2003 
(96) to 2006 (481), where in 29 cases the date granted was 
not found. In 2007, the number of new writs fell by 46.7%, 
totaling 225, but the reasons for this decrease has not yet 
been investigated (Figure 1). Even though the number of 
new suits had fallen in 2007, a commensurate decrease in 
the number of treatments in the same year was not observed. 
This is due to the cumulative characteristic of court actions.
Most of the lawsuits involved chronic illnesses 
such as Type 1 Diabetes Mellitus (25.75%), hypertension 
(9.45%), mood disorders (6.36%), Type 2 Diabetes 
Mellitus (4.40%), lactose intolerance and gastroesophageal 
reflux disease (4.24%), among others.
Older adults (over 60 years old) and children (0 to 
10 years old), represented 47.1% of the total petitioners. 
The most frequent health problems in court actions among 
children were gastroesophageal reflux disease and lactose 
intolerance. The most frequent cause in the 11-15 years 
age group, which accounted for 22.1% of the lawsuits, 
was Type 1 Diabetes.
Insulin was the main request of petitioners who were 
Type 1 Diabetes Mellitus sufferers, corresponding to R$ 
1,242,009.39 (23.24%) of the overall costs with judicially 
demanded drugs (R$ 5,344,274.50). The insulin analogues 
represented 90.91% of insulin units provided and Glargine 
corresponded to 44.20% of the requests, Lispro to 25.82%, 
Aspart to 27.76% and Detemir to 2.22%.
The vast majority of lawsuits were writs of 
mandamus (94.4% of cases), mainly brought by State 
Public Prosecutors while the remainder were in the hands 
of private law offices.
Most petitioners were women, representing 54.5%.
The prescriptions which led to lawsuits were made 
out under the private health system in 56.4% of cases and 
18.1% from the public system whereas in 25.5% of cases 
it was not possible to identify the prescription’s origin.
Petitioners requested 482 different drugs of which 93 
(19.3%) were available at REMUNE, 48 (10%) from the 
High Cost and Specialized Component of Pharmaceutical 
Assistance (SCPA) and 8 (1.7%) existed on both these 
lists. Thus, 333 (69.3%) of the requested drugs were not 
present in any official list of drugs for public distribution, 
however, 139 (41.7%) of this group had at least one 
therapeutic alternative available (Figure 2).
Of the 1.378 lawsuits included in this analysis, 129 
were excluded from the geoprocessing because the address 
was incomplete.
FIGURE 1 - Number of new lawsuits filed against the Municipal 
Health Secretariat and number of current lawsuits (year not 
given in 29 lawsuits), 2003-2007, Goiânia – GO.
FIGURE 2 - Distribution of requested drugs in official lists for public access and existence of therapeutic alternatives. SCPA: 
Specialized Component of Pharmaceutical Assistance; REMUME: Municipal List of Essential Drugs.
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TABLE I - Characteristics of judicial demands by intra-city region with different incomes
 
 
 
Lawsuits grouped by average minimum wage (MW) in respective regions
Type 1 Regions Type 2 Regions Type 3 Regions Type 4 Regions Value p*
0 to 3 MW 3 to 6 MW 6 to 9 MW Over 9 MW
Population 161,627 475,814 247,208 197,893 −
Number of lawsuits filed 89 417 407 336 −
Costs of lawsuits 285,427.58 1,280,606.35 1,826,535.36 1,472,447.36 −
Number of lawsuits per 1,000 
inhabitants
0.55 0.88 1.65 1.70 0.001**
Average cost of lawsuits per 
inhabitant
1.77 2.69 7.39 7.44 0.0001**
Origin of prescriptions by health care service
Average from Public Health 
Service
3.58 3.92 5.17 3.30 0.5
Average from Private Health 
Service
6.00 7.96 21.08 16.92 0.004**
Availability of requested drugs
Average number of standard 
drugs in official lists per 1,000 
inhabitants
0.95 1.68 3.48 3.08 0.0004**
Average number of nonstandard 
drugs in official lists per 1,000 
inhabitants
0.98 1.37 2.74 2.2 0.008**
Average number of 
drugs representing 
pharmacotherapeutic gaps per 
1,000 inhabitants
0.35 0.5 0.98 0.84 0.01
* Kruskal-Wallis test. ** Variable statistically different.
The judicial demand characteristics varied among 
the intra-city regions where breadwinner incomes differed 
and are depicted in Table I.
The number of lawsuits increased as income 
rose, whereby regions with the highest income (Type 
IV Regions) had three times more lawsuits than Type I 
Regions representing the lowest income.
Lawsuit costs also presented a similar profile. The 
average cost of suits brought by petitioners living in 
regions with the highest income (Type IV Regions) was 
higher than from regions with the lowest income (Type1 
Regions), reaching costs four times higher.
There were no significant differences among the 
regions regarding the frequency at which the nonstandard 
drugs were requested or proportion of those which 
represented lack of assistance. 
Although the frequency that petitioners requested 
nonstandard drugs was similar across the regions, it was 
evident that individuals with higher income requested 
more nonstandard drugs, proportionally, than those with 
lower income.
The ABC curve of drugs demanded in regions with 
the highest and the lowest incomes (Regions I and IV, 
respectively) offers some information that helps elucidate 
the differences between these regions. Group A of ABC 
curve is depicted in Table II.
Results showed that bacterial infections was the main 
therapeutic need indicated as the reason for requesting 
drugs in Type 1 Regions, while in Type IV Regions Type 1 
Diabetes Mellitus was the leading reason.
Except for cancer, which represented high costs in 
both regions, the therapeutic indications in Type I Regions 
comprised a mix of illnesses of minor complexity and 
consequently represented lower costs in comparison with 
those in Type IV Regions.
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DISCUSSION
The study results showed that the average cost of 
lawsuits varied among the regional groups. The average 
cost of suits increased with higher average income, being 
four-fold greater in the highest income group compared 
with the lowest.
Some findings may help explain this behavior. 
One important fact is that the petitioners living in the 
wealthiest regions most frequently requested drugs that 
represent new technologies for the treatment of chronic 
diseases. By contrast, residents of regions with lower 
incomes requested treatments for acute diseases, such as 
bacterial infections which, although requiring high-cost 
drugs, require only short-term treatment. Some authors 
have called attention to the inequity caused by so-called 
“Health Judicialization” (Vierea, Zucchi, 2007; Terrazas, 
2008). This study served to verify that individuals living 
in regions with different social characteristics in the same 
city, had different needs concerning the guarantee of 
access to pharmacological treatment as part of their right to 
health care. These differences between socially disparate 
regions may indicate inequality of access to drugs through 
this route. However, there are no satisfactory data to 
affirm that these differences reflect inequity, considering 
inequity as unfair, unnecessary and avoidable differences 
(Whitehead, 1992).
This ecological approach may be useful in planning 
actions and health policies, since it allows tendencies and 
profiles in urban spaces to be highlighted; however it 
should be used with caution and drawing conclusions at 
an individual level from these findings should be avoided.
Both standard and non-standard drugs were 
analyzed. SUS prescribers were expected to recommend 
drugs freely available within the public network, since 
they know the lists of standard drugs. However, it was 
TABLE II - Pharmacological groups and their respective therapeutic indications of group A from the ABC Curve drugs, in decreasing 
order of financial importance in Type I and IV Regions - Goiânia, Goiás. Brazil
Type I Regions Type IV Regions
Pharmacological 
groups
Therapeutic 
indications
Total (R$) Pharmacological 
groups
Therapeutic 
indications
Total (R$)
Antibacterials Bacterial infections 110,548.64 Insulin and 
analogues
Type 1 Diabetes 
mellitus
 670,917.56
Antineoplastics Neoplasia 64,372.20 Antineoplastics Neoplasia 415,742.84
Antidepressives Depression 30,743.18 Glycogenic 
hormones
Human reproduction  75,629.52
Anti-thrombotic 
agents
Cardiovascular 
disease
21,371.44 Antidepressives Depression 72,941.90
Insulin and 
analogues
Type 1 Diabetes 
Mellitus
17,578.15 Bronchodilators Chronic obstructive 
pulmonary disease
 56,302.00
Antiepileptics Epilepsy 17,026.41 Antithrombotic 
agents
Cardiovascular 
disease
 51,923.31
Lipid modifiers 
(HMG reductase 
inhibitors)
Dyslipidemia 11,273.52 Antihypertensives Arterial hypertension  44,948.55
Anti-Retrovirals Retroviral infections 8,001.84 Parathyroid hormone 
analogues
Osteoporosis  30,047.94
Bronchodilators Chronic obstructive 
pulmonary disease
7,716.25 Local anesthetics Local anesthesia  28,038.18
Muscle relaxants Multiple sclerosis 7,656.17 Urologics Erectile dysfunction  19,453.17
Oral hypo-
glycemiants
Type 2 Diabetes 
Mellitus
7,511.40 Antiepileptics Epilepsy  17,415.96
Antiglaucoma 
preparations and 
miotics
Glaucoma 5,102.98 Antibacterials Bacterial infections  15,225.30
Social inequalities in lawsuits for drugs 471
observed that prescriptions of nonstandard drugs were also 
present in prescriptions for SUS patients. 
Some drugs such as those for glaucoma, alcoholism 
and gastroesophageal reflux treatment, among others, 
represented assistance gaps and should have been included 
in at least one list of public distribution thereby enlarging 
and increasing the pharmaceutical assistance coverage.
However, the majority of requested drugs was 
standard or had free therapeutic alternatives available 
under the SUS where other authors had previously 
observed the same pattern (Messeder, Osorio-de-Castro, 
Luiza, 2005; Vieira, Zucchi, 2007; Borges, 2005).  
The request for drugs for conditions, whose treatment is 
already provided free under the SUS, may be explained 
by three reasons. The first is that the petitioners from the 
private health system, the majority of cases in this study, 
may have demanded drugs through the justice system 
because they were unaware of the availability of the drugs 
in the public system, where these users and their respective 
attending physicians or medical practice is out of step 
with the clinical protocols and the programmatic actions 
defined by SUS.
The second reason may be that, even though 
these drugs are present in official lists of drugs for free 
distribution, the petitioners may have faced difficulties 
accessing them. This refers to access in its broader sense, 
i.e., it is not only a question of the medication being 
available but it must also being accessible at the opportune 
moment and when the patient (user) is made to believe and 
feel welcome (Penchansky, Thomas, 1981).
The third reason involves new technologies that 
have not been incorporated to the public health system as 
an alternative to those already existing. Vieira and Zucchi 
(2007) identified qualitative deficiencies in treatments 
offered by the SUS for some diseases, indicating a 
need for review of the existing policies with possible 
inclusion of new technologies. However, this situation 
must be evaluated cautiously, since the existence of a new 
technology does not necessarily imply that it is better than 
those currently available (Rascati, 2010). The SUS must 
be critical and responsible when assimilating technologies. 
Recently, the Pharmacy and Therapeutics Committee 
of the city has reviewed its REMUME (Goiânia, 2010) and 
incorporated a variety of drugs which were the subject of 
frequent judicial requests, amongst them insulin analogues 
and eye drops for glaucoma, indicating the influence that 
judicial demands have on the policy of access to drugs. 
The incorporation of these new drugs into the REMUME 
may indicate a concern by public powers in meeting the 
demands of SUS users. However, we observed variations 
in the lawsuit profiles in terms of needs among the different 
social segments. Consequently the medication access 
policies should be sensitive to these disparities. One of 
these variations is the request for insulin analogues, which 
was a major request among the wealthier segments of 
population, who in turn are not frequent SUS users.
Akin to diabetes, the main diseases reported in the 
suits were of a chronic nature and included metabolism, 
cardiovascular, central nervous system and gastric 
disorders as reported in previous studies (Vieira, Zucchi, 
2007; Silva, Terrazas, 2009; Appio, 2007; Freire, 2003) 
explaining the cumulative nature of suits involving 
medication provision and consequent elevated expenditure 
with this component.
The allocation of a significant part of the invested 
resources in citizens’ health with an assistance-only 
component may jeopardize the sustainability of the health 
care pattern developed. This is because, according to 
Ferraz (2008), when resources are lower than the necessary 
expenditure to cater for needs, two different outcomes can 
be expected as a consequence of this opportunity cost: a) 
assistance for all will be rendered unviable, i.e., it will 
be necessary to reduce the number of beneficiaries; or 
b) adjustment and compatibility between resources and 
expenditure will result in reduced quality of healthcare 
assistance. Given that since 1988 the exclusion of users is 
an unconstitutional act, the more probable and plausible 
alternative is a reduction in the quality of the assistance 
offered.
The imbalance between the constitutional proposal 
of universalization, the integrality of assistance and its 
financing, causes instability in the national health care 
system (Dain, 2007). The costing of drugs requested 
through lawsuits is a challenge to the SUS, and its 
sustainability is at risk while growth is higher than the 
resources available for health care.
A notable finding in this study was the participation 
of the Public Ministry (State Public Prosecutors) (PM) 
as the agent of the court actions in the majority of cases, 
unlike previous studies. Vieira and Zucchi (2007), 
Marques and Dallari (2007) in São Paulo, Pereira et al. 
(2004) in Santa Catarina found private attorneys to be the 
main agents. On the other hand, according to the studies 
by Messeder et al. (2005) and Romero (2008), public and/
or non-profit agents, such as Public Defenders, Model 
Offices and MP (State Public Prosecutors) were the 
predominant agents. However, they all found little or no 
MP participation in cases.
A high participation of the Public Ministry found 
in this study may call into question its legitimacy to file 
lawsuits to defend the interests of single citizens, deviating 
from its constitutional remit. However, the Brazilian 
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Supreme Federal Court (STF) does not perceive court 
actions requesting means of health recuperation in this 
light. According to the courts, health is an inalienable right 
and in such cases, Article 127 of the Federal Constitution 
holds the Public Ministry responsible for acting in the 
defense of these individuals (Brasil, 2009). Moreover, in 
principle it is the role of the Public Defender Offices to 
defend poor SUS users who cannot afford to hire a lawyer 
to represent them in court, but for places where this office 
does not exist, the Public Ministry becomes an alternative 
for these citizens. This is the case of the city studied, and 
helps explain the extensive participation of the Public 
Ministry in the health care lawsuits.
Despite the Public Ministry being a legitimate 
representative of needy individuals, the study observed 
that the majority of lawsuits had originated from urban 
regions associated with the highest incomes. The number 
of actions in the two segments with the highest income 
was 1.5-fold higher than in the two segments with the 
lowest income. Vieira and Zucchi (2007) and Chieffi and 
Barata (2009) also observed a higher number of lawsuits 
originating from regions with better social conditions.
This profile may be associated with the patients’ 
relationship network facilitating access to the necessary 
information to grant their constitutional rights. This is 
relevant because patients are generally unaware of their 
rights until somebody informs/guides them (Leite, Mafra, 
2010) and the physician has an important role in this 
relationship network, acting as the main informer (Leite, 
Mafra, 2010; Terrazas, 2008).
Other differences were observed among regions with 
differing average salaries. One of these differences was 
expected, namely, the origin of prescriptions in the private 
health system was more frequent in segments with higher 
income, i.e., it was expected that people from wealthier 
regions did not use the Unified Health System (SUS), 
opting for supplementary health services, as observed 
in other studies (Terrazas, 2008; Vieira, Zucchi, 2007). 
Looking to the public sector to overcome lack of access 
and integrality of care in a public/private mix are measures 
people resort to in their health care quotidian influenced 
by health plan coverage (Leite, Mafra, 2010).
The health judicialization phenomenon has been 
extensively studied and described, along with its 
social, ethical, economic, administrative and sanitary 
consequences. However, this problem interferes in SUS 
management in the three government spheres, with 
greatest impact at municipal level, since cities have tighter 
budgets.
Some related factors include the influence of 
the pharmaceutical industry, high cost of treatment, 
unavailability of drugs under the public health care system, 
among others (Provin, Delduque, Amaral, 2012) although 
only a few of these factors have a well-established cause-
effect relationship. 
Nevertheless, some measures have been adopted in a 
bid to tackle the problem, such as taking the administrative 
route (non-judicial) to request drugs as an alternative to 
the judicial route and the adoption of Technical Chambers. 
However, both these solutions come into play only after the 
demand has been filed, while none propose to deal with the 
root problem, i.e., act in a preventive and efficient manner 
aiming to make demands that are out of flow an exception.
Among the list of causes related to the judicial 
and extrajudicial demands, several are outside the realm 
of SUS management, however, those originating from 
within the health system should be elucidated and their 
relationship with the problems resulting in the demands 
should be determined and addressed via alternative routes. 
Subsequently, these problems should be analyzed in-depth 
in order to tackle the root problem. 
As the problem in hand is multifactorial, there 
may well be no definitive solution to remedy it, but these 
demands should be kept at levels compatible with efficient 
management of public resources while upholding the 
universality and integrality principle.
CONCLUSION
The judicial demand profile in intracity regions with 
different incomes exhibited distinct characteristics, and 
may represent diverse needs in terms of guaranteeing the 
right to health care, particularly concerning the provision 
of drugs. Population segments with higher incomes filed 
lawsuits more frequently to assure their access to drugs 
and also requested more expensive treatments.
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